We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Thousands of children in developing countries die each year from diarrhoea caused by rotavirus. Shortly after RotaShield — a vaccine against the virus — was launched in the late 1990s, it was discovered that the vaccine could lead to a potentially fatal bowel disorder called intussusception. Though the risk was considered low enough to warrant use of the vaccine in the developing world where rotavirus infects 1 in 200 children, it was deemed too high for use in the United States, and production was halted.

In this article, Leslie Roberts describes renewed attempts to create a live oral vaccine. GlaxoSmithKline Biologicals and Merck are the two pharmaceutical players involved and their studies on candidate vaccines, Rotarix and RotaTeq, have the full backing of the Global Alliance for Vaccines and Immunisation.

Although early results are promising, this second attempt is unlikely to be all plain sailing. The diversity of rotavirus varieties could make protection against all or even most strains impossible. Also, clinical trials have not been run in countries in Africa and Asia, which are hit hardest by the disease. If successful, says Roberts, this enterprise could become a model for vaccines against malaria and HIV. If it fails, however, it's back to the drawing board, which means a long wait for poorer nations.

Link to full article in Science

Reference: Science 305, 1890 (2004)

Related topics